After all, recent studies suggest the use of drugs that act on orexinergic receptors also in the treatment of different cancers including colon, pancreas and prostate cancers [54] and neurodegenerative diseases [55,56] such as Alzheimer’s disease (AD) where orexinergic system dysregulation promotes sleep-wake cycle impairment [57] and also interacts with CSF AD biomarkers, such as beta-amyloid and tau proteins. Here, MAPT is linked to Alzheimer disease.